Compare Adaptive Biotechnologies Corp (ADPT) vs abrdn Physical Palladium Shares ETF (PALL) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs abrdn Physical Palladium Shares ETF — how do they compare? Adaptive Biotechnologies Corp trades at $19.94 (market cap $3.33B), while abrdn Physical Palladium Shares ETF trades at $22.15. The key difference: Adaptive Biotechnologies Corp is trading nearer its 52-week high, abrdn Physical Palladium Shares ETF nearer its low. Which is the better fit depends on your goals.
| ADPT | PALL | |
|---|---|---|
Market Cap | $3.33B | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $22.37 | $37.18 |
52-Week Low | $10.24 | $19.96 |
Enterprise Value | $3.19B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
PALL trades at $23.15, up 1.05% today, but technical indicators signal a bearish trend with moving averages and oscillators in sell territory. A 1-for-5 stock split is scheduled for May 18, 2026. Recent news highlights palladium's price weakness as a potential buying opportunity, citing supply risks and industrial demand. The stock faces headwinds from Federal Reserve rate hike expectations and weaker investment demand.
The outlook remains cautious due to bearish technicals and macroeconomic pressures, though some analysts see value at current levels. Key risks include commodity price volatility and interest rate sensitivity. Investors should weigh the ETF's exposure to palladium's supply-demand dynamics against broader market sentiment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About abrdn Physical Palladium Shares ETF
PALL is a physically-backed ETF that tracks the spot price of palladium. It holds physical bullion in secure vaults, offering a liquid way to invest in this precious metal primarily used in automotive catalytic converters and electronics.
Read more on PALL →
